In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

L-2-hydroxyglutarate dehydrogenase (L2HGDH) is a novel metabolic target protecting from cardiac hypertrophy and heart failure

Session Rapid Fire 1 - Basic Science

Speaker Anca Remes

Congress : Heart Failure 2019

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Cardiac Hypertrophy
  • Session type : Rapid Fire Abstracts
  • FP Number : 9

Authors : A Remes (Kiel,DE), L Ding (Kiel,DE), B Kamlage (Berlin,DE), U Rennefahrt (Berlin,DE), S Hille (Kiel,DE), A Jungmann (Heidelberg,DE), K Rapti (Heidelberg,DE), HA Katus (Heidelberg,DE), N Frey (Kiel,DE), OJ Mueller (Kiel,DE)

A Remes1 , L Ding1 , B Kamlage2 , U Rennefahrt2 , S Hille1 , A Jungmann3 , K Rapti4 , HA Katus3 , N Frey1 , OJ Mueller1 , 1University Medical Center of Schleswig-Holstein - Kiel - Germany , 2Metanomics Health GmbH - Berlin - Germany , 3University Hospital of Heidelberg - Heidelberg - Germany , 4University of Heidelberg - Heidelberg - Germany ,


Background: Heart failure is associated with a metabolic switch to glucose oxidation while usage of long chain fatty acids (LCA) is decreased. Using transcriptional profiling in combination with untargeted metabolic profiling in mice subjected to transverse aortic constriction (TAC), we found a downregulation of L2-hydroxyglutarate dehydrogenase (L2HGDH) which is associated with accumulation of its substrate L-2-hydroxyglutarate (L2-HG). L2HGDH is involved in the energy generation process by catalyzing L-2-hydroxyglutarat (L2-HG) to a-ketoglutarate (a-KG), and therefore plays an important role in the tricarboxylic acid (TCA) cycle. However, the potential connection between L2-HG accumulation, L2HGDH down-regulation and heart failure is unclear.

Aim of our study was to investigate whether adeno-associated virus (AAV) 9-mediated cardiac expression of L2HGDH is able to ameliorate the development of heart failure in a mouse model of heart failure due to TAC. 

Methods: C57BL/6N mice were randomly assigned to treatment with AAV9-L2HGDH and vector control (AAV9-luciferase) through tail vein injection. Two weeks later, mice were subjected to TAC surgery. Successful TAC was confirmed by echocardiography 2 days after TAC.

Results: 6 weeks after TAC, AAV9-luciferase control-treated mice showed progressive deterioration of contractile function and left ventricular remodeling. In contrast, over-expression of L2HGDH protein (30%) in AAV9-L2HGDH treated animals was associated with a significantly improved ejection fraction (EF) and fractional shortening (FS) at the end of the study. While AAV9-L2HGDH treated animals revealed an EF of 36.18 ± 6.63 % (n=12, mean± SD) and a FS of 16.72 ± 4.01 % (n=12, mean± SD), AAV9-luciferase treated mice showed a lower EF (20.14 ± 8.24%,  n=15, p<0.001) and a reduced FS (12.66 ± 6.66 %, n=15, p<0.05). Furthermore, AAV9-L2HGDH-treated TAC mice revealed significantly reduced heart weight to tibia length ratios (HW/TL) as indicator of ameliorated cardiac hypertrophy and decreased lung weight to tibia length ratios (LW/TL) as indicator of decreased heart failure when compared to the vector control group (each p<0.01). Quantification of myocyte cross section area confirmed reduced hypertrophy in the AAV9-L2HGDH group (p<0.001). ANP, BNP, RCAN1.1, and RCAN1.4 as molecular markers of heart failure were also considerably decreased in AAV9-L2HGDH-treated mice (p<0.05). In addition, quantification of Masson's trichrom stainings revealed a significant reduction of fibrous tissue in the L2HGDH over-expression group (perivascular fibrosis, p<0.01 and interstitial fibrosis, p<0.001). 

Conclusion: Cardiac over-expression of L2HGDH is able to ameliorate the development of cardiac hypertrophy and fibrosis as well as heart failure in a pressure-overload model. Therefore, upregulation of L2HGDH represents a promising approach for future therapy of heart failure.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are